High Court Lifts Stay On Merck Birth Control Patent Ruling

By Dani Kass (July 27, 2016, 8:58 PM EDT) -- Chief Justice John Roberts on Wednesday lifted a stay on the Federal Circuit's decision that Merck KGaA and Bayer AG's patent claim against Watson Laboratories Inc. is invalid, clearing Watson to move forward with a generic of the birth control drugs Safyral and Beyaz during appeals.

The U.S. Supreme Court chief justice's three-sentence order vacating his July 21 decision, and thereby denying Merck and Bayer's application for a stay, came after Watson told the high court Tuesday that there's no chance of irreparable harm if it's allowed to proceed with a generic. Watson, a unit of Allergan PLC, had also argued...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!